<DOC>
	<DOCNO>NCT02719821</DOCNO>
	<brief_summary>The goal project refine evaluate feasibility brief , behavioral intervention improve recovery follow hematopoietic stem cell transplantation ( HSCT ) . Cancer patient treat HSCT learn behavioral technique improve sleep increase daytime activity goal alleviate insomnia , fatigue , depression HSCT . If intervention feasible acceptable patient , future study test effect large trial , long-term goal improve care quality life cancer survivor recover HSCT .</brief_summary>
	<brief_title>Refining Biobehavioral Intervention Enhance Recovery Following Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description>Details assessment strategy : Patient-reported outcome : Participants complete self-report measure prior HSCT 9 ( mid-intervention ) 18 week ( post-intervention ) post-HSCT . The sleep disturbance , fatigue , depression module NIH Patient Reported Outcomes Measurement Information System ( PROMIS ) primary outcome . The investigator compare performance establish instrument investigation team previously use : Insomnia Severity Index ( ISI ) , Fatigue Symptom Inventory ( FSI ) , Inventory Depression Anxiety Symptoms ( IDAS ) depression subscale . Actigraphy : The Actiwatch-2 ( Philips Respironics ) , wrist-worn actigraphy device , use objectively quantify circadian rest-activity pattern continuous 7-day period use 1-minute sampling epoch three time point : prior HSCT 9 ( mid-intervention ) 18 week ( post-intervention ) post-HSCT . The following index calculate : mesor ( mean activity level ) , amplitude ( rhythm height ) , acrophase ( time day rhythm peak ) , R-squared ( robustness rhythm ) . Participants complete concurrent nightly sleep log , traditional sleep parameter calculate logs actigraphy , include total sleep time ( TST ) , sleep onset latency ( SOL ) , wake time sleep onset ( WASO ) , sleep efficiency ( SE ) . For daytime activity , calibration threshold use aggregate activity data step minute spend sedentary , light , moderate , vigorous activity</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Adults 18 year age old undergoing hematopoietic stem cell transplantation ( HSCT ) University Wisconsin Carbone Cancer Center ( UWCCC ) Autologous transplant recipient multiple myeloma lymphoma ( Hodgkin 's NonHodgkin 's type ) receive standard conditioning regimen Allogeneic transplant recipient undergo fully ablative transplant Participants develop treatment complication disease recurrence enrol study may continue participate able Autologous transplant recipient receive nonstandard regimens Autologous transplant recipient diagnose multiple myeloma lymphoma Allogeneic transplant recipient receive reduced intensity regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Insomnia</keyword>
	<keyword>Depression</keyword>
	<keyword>Behavioral Intervention</keyword>
</DOC>